All In Biotech

Drug Trial Radar · NCT05294458

A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects

A Single Part, Three-Way Crossover, Randomised, Open-Label Study Designed to Evaluate the Relative and Absolute Bioavailability Following a Single Subcutaneous Injection of a Novel High Concentration Subcutaneous Formulation of Cotadutide Against a Low Concentration Subcutaneous Formulation and Intravenous (IV) Formulation for Reference, in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Mar 28, 2022

Primary completion

Sep 12, 2022

Study completion Sep 12, 2022

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Quotient Sciences
First posted
Mar 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Sponsor is developing the test medicine, cotadutide, for the potential treatment of non-alcoholic steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) with chronic kidney disease. This healthy volunteer study will try to identify how two different concentrations of cotadutide are taken up by the body when dosed under the skin (subcutaneous injection). The study will also try to identify the absolute bioavailability of cotadutide (amount taken up by the body when dosed under the skin compared to an injection directly into the vein (intravenous)). This is a single-part, three-period study taking place at one non-NHS site in the UK and will involve 12 male and female (non-pregnant/non-lactating) volunteers aged 18-55. For each study period, on Day 1 volunteers will receive cotadutide as either a subcutaneous injection (into the stomach) or an intravenous injection following an overnight fast of at least 10 hours. The subcutaneous injections will be given as either a 1 mg/ml or 5 mg/ml concentration. The intravenous injection will be given as a 0.1 mg/ml concentration. Volunteers will be discharged on Day 4 and there will be a washout period of 7 days between dosing. Blood samples will be taken at regular intervals for pharmacokinetics and safety assessments from Day -1 to discharge. Volunteers will need to return for a follow up visit 28 (±2) days post-first dose for provisional of an anti-drug antibody sample and to ensure wellbeing

Conditions

  • Non-alcoholic Steatohepatitis
  • Type 2 Diabetes Mellitus (T2DM)
  • Chronic Kidney Disease

Interventions

  • cotadutide solution for injectionDrug

    cotadutide solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute bioavailability of the high and the low concentration cotadutide SC formulationsTime frame: Collection of plasma samples from pre-dose to 72 hours post-dose.
  2. Maximum observed concentration (cmax)Time frame: Collection of plasma samples from pre-dose to 72 hours post-dose.
  3. Relative bioavailability of a high concentration cotadutide SC formulation in comparison to low concentration formulation, in the fasted stateTime frame: Collection of plasma samples from pre-dose to 72 hours post-dose.
  4. Relative bioavailability of a high concentration cotadutide SC formulation in comparison to low concentration formulation, in the fasted stateTime frame: Collection of plasma samples from pre-dose to 72 hours post-dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Ruddington, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.